All 1 tracked stories fall under one category: markets. MillerKnoll is most often covered alongside Fulcrum Therapeutics, which appears in 1 of these 1 story. Their average consequence score of 5 runs below the beat's 6.4 for that window. They are less corroborated than the beat average, carrying 2 original sources each against 2.4 for the same window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about MillerKnoll
All 1 tracked stories fall under one category: markets. MillerKnoll is most often covered alongside Fulcrum Therapeutics, which appears in 1 of these 1 story. Their average consequence score of 5 runs below the beat's 6.4 for that window. They are less corroborated than the beat average, carrying 2 original sources each against 2.4 for the same window. We currently track 1 Finance story that mention MillerKnoll, all published on March 18, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 114 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering MillerKnoll. Shared-story counts are live from our verified record — not editorial picks.
Recent short interest updates for Fulcrum Therapeutics and MillerKnoll signal growing investor caution as both companies navigate critical operational and macroeconomic challenges. While Fulcrum faces clinical-stage volatility following in-line earnings, MillerKnoll contends with a Hold consensus and broader pressure on the office furniture sector.